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Clinically-relevant postzygotic mosaicism
in parents and children with developmental
disorders in trio exome sequencing data
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Mosaic genetic variants can have major clinical impact. We systematically analyse trio exome
sequence data from 4,293 probands from the DDD Study with severe developmental
disorders for pathogenic postzygotic mosaicism (PZM) in the child or a clinically-unaffected
parent, and use ultrahigh-depth sequencing to validate candidate mosaic variants. We
observe that levels of mosaicism for small genetic variants are usually equivalent in both
saliva and blood and ~3% of causative de novo mutations exhibit PZM; this is an important
observation, as the sibling recurrence risk is extremely low. We identify parental PZM in
21 trios (0.5% of trios), resulting in a substantially increased sibling recurrence risk in future
pregnancies. Together, these forms of mosaicism account for 40 (1%) diagnoses in our
cohort. Likely child-PZM mutations occur equally on both parental haplotypes, and the
penetrance of detectable mosaic pathogenic variants overall is likely to be less than half that
of constitutive variants.
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Mosaicism is a well-described biological phenomenon inwhich individuals harbour two or more populations ofgenetically distinct cells as a result of postzygotic
mutation1,2. Mutations that occur during early embryonic mito-
ses can result in somatic and/or germline mosaicism at appreci-
able levels across multiple tissues1,2. However, mosaicism is
frequently overlooked as a source of pathogenic variation in rare
monogenic diseases largely due to the challenges associated
with variant detection3,4. Postzygotic de novo mutations (DNMs)
may result in somatic mosaicism, potentially causing a less severe
and/or variable phenotype compared with the equivalent con-
stitutive mutation, or somatic and gonadal mosaicism, potentially
enabling transmission of a pathogenic variant from an unaffected
parent to their affected offspring (Fig. 1a)3–6. In addition to
making an accurate diagnosis in the child, parental mosaicism
also has important clinical implications for counselling parents
about recurrence risk (Fig. 1b), with substantially increased risk in
parental mosaicism but minimal risk in postzygotic mosaicism
originating in the proband7–10. Numerous cases exist in the lit-
erature of recognised monogenic disorders that are occasionally
caused by mosaic variants11, which can range from small
sequence variants such as single nucleotide variants (SNVs) and
insertion/deletions (indels)12–16, to large structural variants
including copy number variants (CNVs)17,18 and chromosomal
aneuploidy19–21. Mosaic variants have also been shown to con-
tribute to the risk of autism spectrum disorders22,23. Some
pathogenic mosaic variants have been shown to exhibit markedly
different abundances in different tissues, due in part to differ-
ential negative and positive selective pressures in different
tissues13,24. This differential tissue representation can be clinically
relevant, particularly as some pathogenic mosaic mutations are
typically absent from tissues commonly sampled for genetic
testing, i.e. blood13,17. It is not known how common this phe-
nomenon of differential tissue representation is for mosaic
pathogenic sequence variants across different disorders.
Despite its clinical importance, postzygotic mosaicism (PZM)
can easily be missed or the variants wrongly assumed to be
constitutive due to the technical challenges inherent in the
detection of alleles present in only a subset of cells. Next-
generation sequencing (NGS) technologies offer an opportunity
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Fig. 1 Timing of de novo mutations. a De novo mutations (DNMs) can occur at any point prior or during development of the embryo, potentially resulting in
mosaicism. The most common form of DNM (left) occurs in the parental gametes and is constitutive in the child. A postzygotic (PZM) DNM in the parent
(middle) results in mosaicism across multiple parent tissues and a constitutively inherited variant in the child when the parental gametes are affected. A
PZM DNM in the child (right) is not present in any parental tissue but is mosaic in the child. b Sibling recurrence risk varies with timing of PZM, from very
low in child-PZM, to medium in parent-PZM, to high (50%) in affected parents with constitutive pathogenic variants. Different types of mosaic variants
can be misclassified by standard variant callers, resulting in erroneous risk estimation or missed diagnoses
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to detect lower levels of mosaicism more readily than was pre-
viously possible using either capillary sequencing or microarray-
based techniques25–27. Standard whole-exome sequencing (WES)
typically produces data of >30X average depth, allowing detection
of alleles only present in a small fraction of reads28, while
ultrahigh-depth (>10,000X) sequencing technologies can be used
to detect or confidently confirm mosaic variants present in just a
tiny fraction of cells29. However, using NGS technologies, mosaic
variants present in the majority of cells will often be detected by
variant calling tools optimised for constitutive variation and may
therefore falsely be assumed to be constitutive. This can lead
to under-appreciation of mosaicism in probands and over-
estimation of recurrence risks. More importantly, falsely classi-
fying parental PZM as constitutive in both parent and child can
lead to missed diagnoses due to the exclusion by bioinformatics
pipelines of variants inherited from unaffected parents under the
Mendelian assumptions that are typically applied in fully pene-
trant conditions.
Large-scale analyses of mosaic pathogenic structural variants
has been highly informative for determining the relative con-
tributions of different classes of variants, especially in develop-
mental disorders18,21. By contrast, the study of parental and child
mosaicism of pathogenic small sequence variants has been rela-
tively piecemeal, focused primarily on specific disorders or sub-
types of mosaicism16,22,25,28,30. Larger-scale analyses of likely
benign sequence variants has been informative about the general
properties of post-zygotic mutations9,10. A large-scale systematic
analysis of mosaic pathogenic sequence variants is needed to
determine the relative impact of different classes of mosaicism to
disease.
We have previously used trio-WES and SNP-array data from
the Deciphering Developmental Disorders (DDD) Study to detect
pathogenic mosaic structural variants in children with severe
developmental disorders, and found substantial differences in
copy number and loss-of -heterozygosity events between
blood and saliva (mosaic variants in saliva were often absent
from blood)17,18. Because of the large burden of pathogenic
DNMs in developmental disorders31, which account for around
three-quarters of the total diagnostic yield in this cohort32,33,
we hypothesised that an appreciable number of pathogenic
mutations were likely to be mosaic.
Here, we analyse trio-WES data from 4293 parent-offspring
families in the DDD Study34 to find pathogenic PZM—either in
the affected child (child-PZM) or an unaffected parent (parent-
PZM)—that might be incorrectly annotated or missed by stan-
dard NGS pipelines (Fig. 2). We apply lenient thresholds to
identify candidate pathogenic PZMs with to ensure high sensi-
tivity and use targeted ultra-deep sequencing to comprehensively
validate candidate PZMs. For child-PZM, we observe that the
level of mosaicism is usually equivalent in both saliva and blood,
and estimate that ~3% of causative de novo mutations exhibit
PZM. Likely child-PZM mutations occur in equal proportions on
the maternal and paternal haplotypes and, unlike constitutive
DNMs, show no evidence of a parental age effect. We observe a
marked reduction in the enrichment of damaging, likely patho-
genic DNMs in known DD-associated genes with reducing levels
of mosaicism.
We also identify parental PZM in 21 trios and overall detect 40
(1%) diagnoses resulting from mosaic variants in our cohort.
Results
Postzygotic mosaicism in the child (child-PZM). To analyse
child-PZM, we identified a high-sensitivity set of 8464 candidate
DNMs in 4293 children with DDs from trio-WES data using
saliva-extracted DNA or blood-extracted DNA in around a third
of probands (as previously described31). We designated 1000 loss-
of-function (LOF) and functional DNMs in autosomal dominant
DD-associated genes and X-linked dominant DD-associated
genes in females as being likely pathogenic and plausibly causa-
tive, and 1490 synonymous DNMs in non-DD-associated genes
as being likely benign and unrelated to the DD. To select can-
didate mosaic DNMs, we used a variant prioritisation strategy
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Fig. 2 Variant selection flowchart. Flowchart outlining variant selection for high-depth sequencing validation experiments. Candidate DNMs from trio
exome sequencing were used to select candidate mosaic DNMs in the proband (blue) as well as ‘low level’ mosaic variants in a parent (light red) for
validation; candidate inherited variants were used to select ‘high level’ mosaic variants in a parent (dark red) for ultrahigh-depth sequencing
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(see Methods) based on deviation of the proband variant allele
fraction (VAF, defined as the number of alternative reads divided
by the total read depth) from a binomial distribution centred
around 0.5. Using this strategy, we selected 106 likely pathogenic
DNMs and 143 likely benign DNMs (of which 81 had both saliva
and blood-extracted DNA samples available) for ultrahigh-depth
sequencing in all members of the trio. Of the likely pathogenic
DNMs: 31/106 validated as mosaic DNMs in the proband
(31/1000 or ~3% of likely pathogenic DNMs), of which 20 could
be assayed in both blood and saliva samples; 64 validated as
constitutive DNMs; three were false positives; and the validation
data were uninformative in eight cases (Fig. 3 and Supplementary
Fig. 1). Of the likely benign variants: 48/81 validated as mosaic
DNMs in both blood and saliva samples (48/1490 or ~3% of
benign DNMs); eight validated as constitutive DNMs; 23 were
false positives; and the validation data were uninformative in two
cases (Fig. 3 and Supplementary Fig. 1).
Validated VAFs of mosaicism in the proband varied from
0.04–0.39 (equivalent to presence of the variant in 8–80% of
cells). Similar levels of mosaicism were observed in saliva and
blood (Fig. 4) in both likely pathogenic and benign variants, apart
from two likely pathogenic variants in SCN1A and SCN8A that
appeared to have significantly higher VAF in saliva than blood.
SCN1A has previously been shown to harbour differential levels
of mosaicism across different tissues35, and both genes are well-
known sources of mosaic diagnoses in epilepsy30,36,37. The
likelihood that a variant validated as mosaic in the proband was
strongly correlated with both the WES variant allele fraction
(VAF) and the strength of statistical evidence (binomial p-value)
for a deviation of VAF away from 0.5 (Table 1 and
Supplementary Fig. 1). Twenty-four of the 31 mosaic DNMs
were considered to be definitely or likely pathogenic for DD
following a detailed clinical evaluation; the remaining seven
variants were considered benign either due to a lack of clinical fit
(n= 4) or the presence of another more plausible genetic
diagnosis (n= 3). The children with diagnoses in genes that
cause well-known syndromes had phenotypes consistent with
those syndromes. We were unable to determine whether the
phenotypes were milder as a result of mosaicism, as knowledge of
the phenotypic spectrum and individual developmental profiles of
the specific disorders is limited and, together with the small
numbers of affected patients, constrains drawing definitive
conclusions. However, we identified a mosaic (VAF= 0.33)
LOF variant in KMT2D that was considered fully diagnostic but
had an intermediate methylation signature that failed to classify
as either benign or pathogenic (Fig. 5).
Postzygotic mosaicism in the parent (parent-PZM). We took
two complementary approaches to evaluate parent-PZM. First, to
detect low-level parental mosaicism where the variant is not
called in the parental sample by standard variant calling algo-
rithms, we started with the same list of 1000 likely pathogenic
candidate DNMs described above and selected all variants with
one or more alternative allele reads in a single parent for
ultrahigh-depth sequencing. Of the 72 candidate variants: eight
were validated as constitutive in the proband and mosaic in a
parent (1% of the likely pathogenic DNMs), five maternal and
three paternal; 53 variants were validated as true DNMs in the
proband but absent from the parent; one variant was constitutive
in both the parent and proband; six variants were false positives;
and the validation data were uninformative in four cases. The
number of alternate reads in the parent was highly correlated with
the likelihood of validating as parent-PZM: with just a single alt
read (n= 60), only 5% of sites validated as mosaic, while 42% of
sites with two or more reads validated as mosaic in the parent
(n= 12) (Table 1 and Supplementary Fig. 2). Thus, the majority
of candidate sites in which a single read supporting the alternate
allele was observed in the parental exome data were due to
sequence errors and not mosaicism, and is consistent with the
previously estimated sequencing error rate of the Illumina
sequencing platform and the depth of exome sequencing in this
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Fig. 4 Levels of mosaicism in saliva versus blood Comparison of the
validated mosaic fraction using ultrahigh-depth sequencing in blood. versus
saliva for mosaic DNMs that are either plausibly pathogenic loss-of-
function (LOF) or functional variants in known developmental disorder
genes (DDG2P, open diamonds), or likely benign synonymous variants in
genes not currently associated with developmental disorders (not-DDG2P,
filled circles). There is generally a good correlation between saliva and
blood VAFs (DDG2P functional, solid line, R2= 0.6; non-DDG2P
synonymous, dotted line, R2= 0.9) and there is no significant difference
between the association of mosaic VAF in saliva versus blood using linear
regression and including DDG2P status as a covariate
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Fig. 3 Summary of validation results for de novo mutations. Comparison of
the variant allele fraction (VAF) from exome sequencing versus from
ultrahigh-depth sequencing for candidate DNMs, separated into validation
classes: constitutive DNM (red), mosaic DNM (blue) and false positive
(green). Validation data from both saliva and blood samples are included
where available. The correlation between exome and validation VAFs (R2=
0.49) includes only mosaic variants
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study38. Validated fractions of low-level mosaicism in the parent
varied from a VAF of 0.005–0.20 (equivalent to presence of the
variant in 1–40% of cells). Six of the eight low-level mosaic
inherited variants were considered to be definitely or likely
pathogenic following a detailed clinical evaluation; one of these
six families had a second sibling with the same disorder
emphasising the importance of this analysis for genetic
counselling.
Second, to detect high-level parent-PZM where the variant is
called in the parental sample by standard variant calling
algorithms (and thus might be assumed to have been constitu-
tively inherited), we identified all 18,527 rare LOF and functional
variants in dominant DDG2P genes detected in the same 4293
children with DD. We then selected 10,721 constitutive
heterozygous variants in the child that were also detected in just
one apparently unaffected parent. Given the low prior likelihood
of inherited variants being pathogenic in this cohort33, the vast
majority of these are expected to be constitutive in the parent and
benign. Using a variant prioritisation strategy based on deviation
of the parental VAF from a binomial distribution centred around
0.5, augmented by knowledge of known pathogenic variants, LOF
variants and probands with affected siblings (see Methods), we
selected 36 candidate parental mosaic variants for validation
using ultrahigh-depth sequencing. Of these: 13 variants validated
as constitutive in the proband and mosaic in a parent (<0.1% of
all inherited rare LoF and functional variants in DDG2P genes),
Table 1 Metrics for identifying different types of mosaic variants from whole exome sequencing data. Values are based on ultra-
high-depth sequencing validation results, and any uninformative results were excluded
Type of mosaicism Variant caller Mosaic
prioritisation
Validated mosaic Validated
constitutive or FP
Sensitivity Specificity PPV NPV
De novo (child-PZM) DNG Binomial p < 0.0001 56 17 69% 84% 73% 80%
Binomial p≥ 0.0001 24 81
VAF < 0.27 63 32 78% 68% 64% 84%
VAF≥ 0.27 17 66
Inherited (low-level
parent-PZM)
DNG <2 alt reads in
one parent
3 57 63% 89% 42% 95%
≥2 alt reads in
one parent
5 7
Inherited (high-level
parent-PZM)
GATK Binomial p < 0.0001 9 7 69% 67% 56% 78%
Binomial p≥ 0.0001 4 14
VAF < 0.27 13 12 100% 43% 52% 100%
VAF≥ 0.27 0 9
PZM postzygotic mosaicism, DNG DeNovoGear, GATK Genome Analysis Toolkit, VAF variant allele fraction from exome sequencing data, FP false positive, Binomial p= binomial test on the alternative
allele reads, centred around 0.5, PPV positive predictive value, NPV negative predictive value
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Fig. 5Mosaic DDD proband with an intermediate methylation profile. We evaluated DNA methylation at ~850,000 CpG sites across the genome in a subset of
individuals from the DDD study using an Illumina EPIC methylation array. The blue cloud represents the distribution of published pathogenic KMT2D variants
(n= 12), and the orange cloud non-pathogenic KMT2D variants (n= 15) from the published test set44. The points in red, orange, and blue represent methylation
profiled non-mosaic KMT2D cases and negative controls from the DDD study; one DDD proband with a mosaic KMT2D stop-gain DNM (black triangle, VAF=
0.33) failed to classify as a case and sits between the two clusters
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eight maternal and five paternal; 21 were constitutive in both the
parent and proband; and the validation data were uninformative
in two cases. The likelihood that a variant validated as mosaic in
the parent was correlated with both the parental VAF and the
strength of statistical evidence (binomial p-value) for a deviation
of VAF away from 0.5 (Table 1). Levels of mosaicism in the
parent varied from 0.06–0.33 (equivalent to presence of the
variant in 12–66% of cells). Ten of the 13 high-level mosaic
inherited variants were considered to be definitely or likely
pathogenic for DD following a detailed clinical evaluation; two of
these ten families had a second sibling with the same disorder,
though they were prioritised for validation on the basis of VAF
rather than their presence in affected sib pairs.
Comparing analytical approaches to identify PZMs. The diag-
nostic yield from these combined mosaic analyses was ~1%, and
the 40 validated definitely or likely pathogenic mosaic variants are
summarised in Supplementary Data 1. The best method for
detecting mosaic variants from trio-WES data depends upon the
type of mosaicism: for high-level mosaicism (child-PZM or par-
ent-PZM), VAF is both intuitive and sensitive for detecting
mosaicism, while the binomial p-value is more specific as it takes
into account read depth. Using our exome sequencing trio data,
0.1 < VAF < 0.27 or binomial p-value < 0.0001 are good predictors
of high-level mosaicism. For low-level mosaicism, where the
variant is not detected using standard algorithms and thus we
were only able to evaluate it here for parent-PZM, observing two
or more reads supporting the variant allele in a parent is a good
predictor parent-PZM in putative DNMs (Table 1).
The level of mosaicism detected with ultrahigh-depth sequen-
cing was significantly higher for child-PZM than for low-level
parent-PZM (p= 9.3 × 10−5) and higher for high-level than low-
level parent-PZM (p= 0.0053, Fig. 6). These results support the
intuitively attractive hypothesis that the level of mosaicism is
correlated with the likelihood of having a pathogenic impact. To
assess this hypothesis more formally, we grouped variants from a
high-stringency set of candidate DNMs (defined by setting
filtering thresholds to ensure that the number of observed
synonymous DNMs equalled the number expected under a null
mutation model, i.e. assuming no enrichment for synonymous
DNMs in our cohort)31 into six bins of proband VAF (see
Methods). We further subdivided the DNMs into classes of
variant consequence (LOF and functional versus synonymous)
and types of genes (known DD-associated genes versus all genes,
Table 2). The previously observed enrichment31 of both LOF and
functional DNMs in DD-associated genes in our cohort is
substantially reduced for mosaic variants (p= 0.0001). The
correlation between enrichment of potentially damaging variants
and increasing VAF is greater in classes of genes where the
variants are more likely to cause monogenic developmental
disorders (Fig. 7). The linear regression coefficient for genes not
currently known to be DD-associated was not significantly
different from the null (p= 0.03), while the regression coefficients
were significantly different for either DD-associated (p= 0.00007)
or monoallelic DD-associated genes with a loss-of-function
mechanism (p < 0.00001). For likely mosaic variants (VAF <
0.27) in known DD-associated genes with a monoallelic loss-of-
function mechanism, the enrichment of LOF and functional
variants is reduced to approximately a third that of constitutive
variants (p= 0.04).
Using just high-stringency candidate DNMs where it was
possible to ascribe the mutation to either the maternal or paternal
haplotype (n= 771, see Methods), the enrichment of paternal-
origin mutations was significantly different (p= 0.0001) between
mosaic (n= 41) and constitutive variants (n= 730). We visually
inspected IGV plots for all 41 candidate mosaic DNMs with a
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Fig. 6 Levels of mosaicism across validation experiments Boxplot of estimated level of mosaicism in validated mosaic DNMs, expressed as the variant allele
fraction (VAF) from ultrahigh-depth sequencing, in the proband (blue) versus the parents (red). Parental variants are split into two distinctive groups: ‘low
level’ (Parental/DNM, light red), which may be erroneously mistaken for DNMs in the child, and ‘high level’ (Parental/INH, dark red), which may be
erroneously mistaken for constitutively inherited variants. P-values calculated using a Mann–Whitney–Wilcoxon test in R. Centre line=median; bounds of
box= interquartile range; whiskers= quartile ± 1.5 × interquartile range
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nearby informative allele inherited from a single parent on the
same read-pair. For all validated cases (n= 6), we observed the
characteristic three-haplotype pattern expected for mosaic
variants, and the average VAF of the inherited allele was 0.5;
across all 41 variants, there is a significant difference between the
VAF of the candidate mosaic DNM and the inherited variant (p <
2e-10, Supplementary Fig. 3), supportive of most of the variants
being mosaic. Unlike constitutive de novo mutations, which occur
more frequently in the paternal gametes and show a strong
paternal age effect31,39, the ratio of candidate mosaic variants on
the paternal versus maternal haplotype was 0.95 (21:20),
consistent with a 50:50 ratio expected for a postzygotic mutation
arising during early embryo development, before sexual differ-
entiation. Moreover, mosaic variants did not increase appreciably
with parental age and the relationship between the number of
mosaic DNMs per person and increasing parental age was not
significantly different from the null (Supplementary Fig. 4).
Discussion
We have described an approach for detecting mosaic variants
caused by postzygotic DNMs in either a proband or an unaffected
parent from trio-WES data. As a result of these analyses, we have
made 40 mosaic diagnoses in our cohort of 4293 children with
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Fig. 7 Enrichment of damaging variants with level of mosaicism. The exome sequencing variant allele fraction (VAF) for candidate DNMs is plotted against
the number of damaging (loss-of-function and functional) variants divided by the number of synonymous variants in each of six VAF bins (0.10– < 0.15,
0.15– < 0.20, 0.20– < 0.25, 0.25– < 0.30, 0.30– < 0.35 and >0.35). The number of variants in each VAF bin was further divided into three subgroups of
genes, and the significance of the linear regression coefficient versus the null was assessed using a Z-test: genes not currently known to be DD-associated
(Not-DDG2P, gray; p= 0.03), genes known to be DD-associated (DDG2P, orange; p= 0.00007), and known monoallelic DD-associated genes with a
loss-of-function mechanism (DDG2P-MonoLOF, magenta; p < 0.00001). Gray zones represent 95% confidence intervals. Null values assuming no
enrichment (dotted black line) were calculated from published values of expected numbers of variants in each class based on ExAC, adjusted for indels, and
summed across all genes
Table 2 Summary of candidate DNMs observed in 4293 DDD trios, sub-divided by variant allele fraction, variant consequence
and gene class. Note this table includes all candidate DNMs; it is not limited to those with validation data, and thus includes
some likely false positives particularly at lower VAFs
All genes All DDG2P genes MonoLOF DDG2P genes (LOF+Func)/Syn variants
VAF bin Mean VAF Func LOF Syn Func LOF Syn Func LOF Syn Func LOF Syn
0.10–<0.15 0.14 10 1 7 3 0 1 1 0 0 1.57 3.00 –
0.15–<0.20 0.18 81 18 33 5 3 3 3 2 0 3.00 2.67 –
0.20–<0.25 0.22 99 35 42 16 8 4 6 4 1 3.19 6.00 10.00
0.25–<0.30 0.27 135 58 53 23 21 5 7 15 2 3.64 8.80 11.00
0.30–<0.35 0.33 266 81 69 54 31 10 17 23 3 5.03 8.50 13.33
0.35–1.00 0.49 3709 1224 1084 673 488 112 302 389 28 4.55 10.37 24.68
Total 0.46 4300 1417 1288 774 551 135 336 433 34 4.44 9.81 22.62
VAF variant allele fraction from exome sequencing data, LOF loss-of-function variants, including splice donor, splice acceptor, stop gained, frameshift and initiator codon variants, Func functional variants,
including variants include missense, in-frame deletion and in-frame insertion variants, Syn synonymous variants, DDG2P developmental disorders gene-2-phenotype list (July 2015 version), MonoLOF
monoallelic and loss-of-function mechanism
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severe developmental disorders, of which 24 are child-PZM and 16
are inherited parent-PZM (Supplementary Data 1). The clinical
implication is substantially different between these two groups: the
recurrence risk in future siblings of children with child-PZM is
negligible, while that of children with inherited parent-PZM is
perhaps as high as 50% depending upon the level of parental
mosaicism7–10, and indeed three of our 16 probands diagnosed with
inherited parental mosaic variants have siblings with the same
disorder.
In principle, diagnoses of DNMs could be split into three
groups based on risk of recurrence in future siblings: moderate
(parental somatic mosaicism, ~1–2% of DNMs), low (no parental
somatic mosaicism but possible parental gonadal mosaicism,
~95% of DNMs) and minimal (child mosaic, ~3% of DNMs). The
overlapping VAF distributions of PZMs in affected probands and
apparently unaffected parents (Fig. 6) indicates that different levels
of mosaicism may be necessary for pathogenicity in different genes
or developmental phenotypes40,41, and highlights the importance
of considering variants called in parents as well as apparent DNMs
to capture the full range of parental mosaicism. We estimate that,
in our cohort, likely pathogenic mosaic DNMs are enriched in
DD-associated genes at around half the level observed for con-
stitutive DNMs (Fig. 7). While the penetrance of pathogenic
DNMs undoubtedly increases with increasing VAF, pathogenic
PZMs are still likely associated with reduced reproductive fitness.
This suggests that the VAF distribution of pathogenic PZMs in
unaffected parents is likely to be depleted of higher VAFs com-
pared to benign PZMs, which brings into question the accuracy of
recurrence risk calculators based on benign PZMs9. Importantly,
we observe that, unlike constitutive DNMs, likely child-PZM
shows no parental bias or evidence of a parental age effect.
The clinical relevance of detecting mosaicism is not limited to
counselling of recurrence risks. An increasing number of devel-
opmental disorders also have confirmatory biomarker assays
whereby informative molecular signatures help to distinguish
pathogenic and benign variants and classify variants of uncertain
significance42–44. Detecting mosaicism is important for accurate
interpretation of confirmatory biomarker assays, wherein a
mosaic individual may exhibit an intermediate result that may get
mis-interpreted. To exemplify this, we observed a DDD partici-
pant with a validated diagnostic child-PZM LOF variant in
KMT2D who exhibited an intermediate biomarker phenotype for
a published DNA methylation signature for Kabuki syndrome
caused by mutations in KMT2D44 (Fig. 5). Caution should
therefore be used when evaluating the likely pathogenicity of
mosaic variants using molecular biomarkers.
Our finding that ~3% of DNMs are mosaic is lower than in
some previous studies3,6,22,45, most likely due to differences in
clinical ascertainment, both in terms of phenotype and family
history, and different sensitivity for very low level mosaicism (e.g.
VAF < 0.1). Detecting likely mosaic variants depends on the
depth of the original sequencing data, the error rate of the
sequencing platform, and the metrics used to distinguish different
types of variants. In principle, it should also possible to estimate
the proportion of DNMs that are child-PZMs using mixture
modelling on the VAF distribution of DNMs as compared to
constitutive variants (Supplementary Fig. 5a), obviating the need
for extensive validation. We found that fitting a Gaussian mixture
model to these distributions gives an estimate of 6% of DNMs
that are potentially mosaic (at VAF > 0.1), with mean VAF=
0.198, compared with 0% of the inherited variants (Supplemen-
tary Fig. 5b). This is likely to be an over-estimate compared with
the 3% estimate from our ultrahigh-depth validation experiments,
where around half the candidate variants validated as mosaic,
suggesting that the presence of false positives and constitutive
variants confounds this kind of analysis.
An obvious limitation of our approach was the depth of sequen-
cing (~50X) and, as a consequence, only being able to detect
mosaicism where the fraction was appreciably greater than the
sequencing error rate. Since DeNovoGear requires >2 ALT reads to
detect a variant, we estimate our power to detect child-PZM was
~75% at VAF= 0.1 and ~90% for VAF= 0.2–0.3 (see Supplemen-
tary Fig. 6). We used a high-sensitivity FDR-based approach to
prioritise candidate mosaic variants, and preliminary empirical ana-
lyses suggested that detecting candidate de novo mosaic variants with
a VAF of <0.1 using this strategy would be overwhelmed with false
positives, so we introduced this VAF threshold to focus on a more
tractable VAF range. Although mosaic mutations present in >20% of
cells are more likely to have occurred in early embryogenesis, and
thus have a syndromic developmental impact, future work is needed
to investigate low-level child-PZMs (VAF < 0.1). These limitations
are likely to be common to many existing diagnostic pipelines but
may be reduced by the use of amplification-free whole genome
sequencing, improved modelling of sequencing errors, high-depth
targeted sequencing or long-read sequencing, which would also
improve variant phasing. Validation of very low levels of mosaicism
might also be improved by using unique molecular indexes46,47.
We only had access to DNA extracted from two tissues (saliva
and blood for probands and only saliva for parents) in which to
explore tissue specificity. The correlation between the level of
mosaicism in these tissues versus developmentally-relevant
organs, such as the brain, is unknown and thus caution is nee-
ded when considering the correlation between observed VAF and
phenotype or recurrence risk. Indeed, paternal germline mosai-
cism might be better evaluated using a paternal sperm sample8,48.
Nonetheless, unlike our previous findings on mosaic structural
variants17,18, we did not observe any difference between blood
and saliva samples in the child-PZMs, as might be expected for
PZMs that arise very early in embryogenesis. Although inter-
individual variability and cellular heterogeneity make direct
saliva-blood comparisons challenging49, our results suggest that
concerns about failing to detect pathogenic mosaic variants by
testing blood rather than saliva may be less important for
sequence variants than for structural variants.
In conclusion, using 4293 families with severe developmental
disorders, we have shown that mosaic variants are a significant
cause of rare developmental disorders, and that they can be
detected from standard trio WES. The relatively low proportion
of mosaic variants limited our ability to explore decreasing
pathogenicity with decreasing VAF in a more quantitative man-
ner, as well as evaluate recurrence risk empirically based on
affected siblings, for which much larger cohorts will be needed.
Finally, we did not have sufficient numbers of variants in any
given gene to assess whether mosaic DNMs in the proband
reduced the severity or expressivity of the child’s developmental
phenotype relative to constitutive DNMs. There is now a need for
very large-scale studies to address remaining questions and fur-
ther refine our current findings regarding the relationship
between variant pathogenicity and mosaicism level, further
investigate tissue specificity (including gametes) and empirically
estimate the recurrence risk from siblings. To empower this
research endeavour, as well as increase diagnostic yields and
improve clinical management, algorithms tuned to detecting
mosaic pathogenic variants—particularly in an unaffected parent
—should be integrated into paediatric genomics pipelines.
Methods
Patient recruitment and data collection. The DDD Study has UK Research
Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC,
and GEN/284/12 granted by the Republic of Ireland REC). Patients with severe,
undiagnosed developmental disorders and their parents were recruited and sys-
tematically phenotyped by the 24 Regional Genetics Services within the United
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Kingdom (UK) National Health Service and the Republic of Ireland. Clinical data
(growth measurements, family history, developmental milestones, etc.) were col-
lected using a standard restricted-term questionnaire within DECIPHER50, and
detailed developmental phenotypes for the individuals were entered by the patient’s
clinician using Human Phenotype Ontology (HPO) terms51. Saliva samples for the
family trio as well as blood-extracted DNA samples for the probands were collected
and processed as described previously52. Trio exome sequencing was performed on
either saliva or blood using Illumina HiSeq (75-base paired-end sequencing) with
SureSelect baits (Agilent Human All-Exon V3 Plus and V5 Plus with custom ELID
C0338371). Mapping of short-read sequences for each sequencing lanelet was
carried out by the Wellcome Sanger Institute’s Human Genetics Informatics team
using the Burrows-Wheeler aligner (BWA; version 0.59)53 backtrack algorithm
with the GRCh37 1000 Genomes Project phase 2 reference (also known as hs37d5).
Sample- level BAM improvement was carried out using the Genome Analysis
Toolkit (GATK; version 3.1.1)54 and SAMtools (version 0.1.19)53. Average read
depth in the coding regions across these samples was 50X. Single nucleotide var-
iants and indels were called using the GATK HaplotypeCaller (version 3.2.2) and
GATK resource bundle (version 2.2)55, run in multi-sample calling mode using the
complete data set. We used DeNovoGear (DNG, version 0.54)56 to detect likely
DNMs from trio exome BAM files. Variants were annotated with minor allele
frequencies (from 1000 Genomes Project57, the UK10K cohort58, the Exome
Aggregation Consortium59, and internal data from unaffected parents in the DDD
Study) and the predicted consequence (using Ensembl Variant Effect Predictor49).
The data are available under managed access from the European Genome-
phenome Archive (Study ID EGAS00001000775), and likely diagnostic variants are
available open access in DECIPHER51.
Variant filtering and selection. We generated a high-sensitivity set of 8542 rare
(MAF < 0.01) candidate DNMs from 4293 WES trios. To assess the burden of
mosaic SNVs and indels, we calculated the expected number of DNMs as described
previously58,60 based on gene-specific mutation rates that account for gene length
and sequence context31, and increased the stringency of called DNMs until the
number of observed synonymous variants equated that expected under the null-
mutation model, as published previously31. Using this high-stringency set of DNMs,
we calculated the proband variant allele fraction (VAF)—defined as the read depth
of the alternative allele divided by the total read depth—and calculated the binomial
probability of the observed VAF given an expected VAF of 0.5 (i.e. a constitutive
heterozygous variant). When identifying candidate DNMs, we applied a filtering
threshold on proband VAF > 0.1 due to the difficulty of distinguishing real variants
from sequencing errors at lower VAF in WES data of ~50X average depth. As a
consequence, all candidate DNMs in this dataset had a proband VAF > 0.1.
To determine the parental origin of child-PZMs, we used informative SNVs
inherited from a single parent on the same read-pair as the candidate DNM to
determine whether the variant occurred on the maternal or paternal haplotype. To
assess how variant pathogenicity varies with the level of mosaicism, we also
calculated the number of different classes of DNMs in six bins of increasing
proband VAF (0.10– < 0.15, 0.15– < 0.20, 0.20– < 0.25, 0.25– < 0.30, 0.30– < 0.35, >
0.35), excluding variants that fell below our stringency threshold or were on the X or
Y chromosomes in males. We annotated variants with predicted loss-of-function
(LOF; splice donor, splice acceptor, stop gained, frameshift, initiator codon) or
functional consequences (functional; missense, inframe deletion, inframe insertion)
in dominant genes known to cause developmental disorders (DDG2P, July 2015
version; www.ebi.ac.uk/gene2phenotype). We then calculated the ratio of potentially
damaging (LOF and functional) DNMs to synonymous DNMs in each VAF bin and
compared the linear regression coefficients for different classes of genes.
Candidate PZMs were selected for validation by ultrahigh-depth sequencing
based primarily on statistical deviation from a VAF of 0.5. To limit the dataset to
potential diploid mosaicism, we restricted our analysis of DDG2P genes to those
with autosomal dominant inheritance and X-linked dominant inheritance in
female probands, and to enrich our dataset for the most likely pathogenic LOF
variants, further focused on genes known to cause disease via a LOF mechanism.
Variants were then analysed under the following models:
(1) Apparent DNMs: we analysed our high-sensitivity set of 8,464 candidate
DNMs (8,542 candidate DNMs excluding 78 X-chromosome variants in
boys) under two scenarios:
a. Candidate child-PZM: a binomial p-value for the proband VAF was
calculated assuming a mean of 0.5 then two classes of variants selected
for validation:
i. Likely pathogenic DNMs: LOF and functional variants in dominant
DDG2P genes (n= 1,000) with a false discovery rate (using
binomial p value) of <0.2 (n= 106).
ii. Control variants: synonymous variants in non-DDG2P genes (n=
1,490) with a false discovery rate of <0.05 (n= 143).
b. Candidate low-level parent-PZM: candidate likely pathogenic DNMs
(see above) with any alternative allele reads in one parent were selected
for validation (n= 72).
(2) Apparent inherited variants—candidate high-level parent-PZM: we identi-
fied 18,527 rare (MAF < 0.001) inherited heterozygous LOF and functional
variants in dominant DDG2P genes in 4293 probands, and annotated them
with reference and alternative allele read depths across all members of the
trio. We excluded variants in children with affected parents, with reads
supporting the mutant allele in both parents, or with proband VAF > 0.7 or
<0.3, leaving 10,721 candidates. To maximise the detection of clinically
relevant parent-PZMs, we adopted three different strategies to identify 36
candidate parent-PZMs for validation from this long list of possible
candidates:
a. The binomial p-value for parental VAF was calculated assuming a mean
of 0.5; variants were then selected for validation using a false discovery
rate (Benjamini-Hochberg) of <0.1 (n= 20);
b. We identified a subset of variants with a high likelihood of
pathogenicity (protein-truncating variants and known pathogenic
variants) and parental VAF < 0.4 (n= 10);
c. We identified variants present in affected sib pairs with parental VAF <
0.4 (n= 6).
Experimental validation. Validation of PZM candidates was performed using PCR
amplification followed by Illumina MiSeq (250 bp paired-end reads) in all members
of the trio, with 40 ng of genomic DNA as template and primers designed to
amplify 150–250 bp products centred around site of interest. Median depth of
coverage across all validations was 100,032 reads. Both saliva-extracted and blood-
extracted DNA samples from the proband were assayed where available; only
saliva-extracted DNA was available for parents. Variant inheritance was classified
automatically using an in-house pipeline previously described61 and manually
confirmed in IGV44. Variant pathogenicity was assessed, for each variant, by at
least two consultant clinical geneticists through a composite approach of patient
assessment, variant evaluation, inheritance and clinical fit compared with pre-
viously published cases of children with pathogenic (usually constitutive) variants
in the same gene. A full list of validated mosaic variants is provided in Supple-
mentary Data 2.
To investigate the effect of mosaic mutations on a clinically relevant biomarker,
we evaluated DNA methylation at ~850,000 CpG sites across the genome in a
subset of individuals from the DDD study using an Illumina EPIC methylation
array. A DNA methylation signature that discriminates between benign and
pathogenic KMT2D variants was derived as described previously44 using published
data (GEO: GSE97362). CpG sites with at least 10% differential methylation
between KMT2D and control samples in the training set were identified and
restricted to an FDR < 0.01 using a Mann-Whitney U test at each probe; the
resulting CpG sites (n= 112) form the methylation signature for KMT2D. We
applied this signature to 29 DDD probands profiled on the EPIC array, nine of
whom had KMT2D de novo mutations of uncertain pathogenicity and 20 were age
and sex matched negative controls. We assessed DNA methylation status at
signature CpG sites using the Pearson correlation approach described previously44
using all 29 DDD probands and an additional 27 KMT2D variants of uncertain
pathogenicity from the published test set44.
Data availability
All diagnostic variants linked to phenotypes are available via the DECIPHER database
(https://decipher.sanger.ac.uk/). DDD Study data is available under managed access via
the European Genome-phenome Archive (https://ega-archive.org/studies/
EGAS00001000775).
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